CD39 has the potential to act as a prognostic biomarker for various types of tumors, including head and neck squamous cell carcinoma, NSCLC, cholangiocarcinoma, gastric cancer, colorectal cancer, and ovarian cancer [26, 65, 75, 134, 136, 157]. This evidence concerns the gene ENTPD1 and gastric cancer.